公司业务与行业背景 - 公司专注于开发、生产和销售先进诊断及治疗产品 核心专长为肿瘤学和心血管护理领域[3] 财务表现与业绩变动 - 第二季度收入下降至3.78亿美元 同比下滑4.1%[4] - 核心产品PYLARIFY销售额大幅减少至2.506亿美元 同比下降8.3%[4] - 季度业绩未达市场预期 同时下调2025年全年收入和每股收益指引[4] 市场动态与竞争环境 - 业绩下滑主因PSMA PET成像市场竞争加剧导致部分客户战略收缩[4] 股价表现与市场反应 - 业绩公告当日股价单日暴跌20.76美元 跌幅达28.58%[5] - 股价收盘报51.87美元 创显著单日跌幅纪录[5] 法律与监管动态 - 律师事务所正就公司涉嫌违反联邦证券法展开调查 焦点在于可能存在的误导性商业信息披露[1][2]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lantheus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lantheus between February 26, 2025 and August 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 11, 2025 (GLO ...

诉讼事件概述 - 律师事务所Kessler Topaz Meltzer & Check, LLP对Lantheus Holdings, Inc (NASDAQ: LNTH)提起证券集体诉讼 代表在2025年2月26日至2025年8月5日期间购买或获得公司证券的投资者 [1] - 主要原告申请截止日期为2025年11月10日 [1][3] 指控内容 - 被告被指控在集体诉讼期间作出虚假和/或误导性陈述 未能披露PYLARIFY竞争地位的真实情况 [2] - 公司未能适当评估PYLARIFY的定价和竞争动态 且未披露2025年初的涨价行为尽管此前存在价格侵蚀 却为竞争性定价创造了机会 [2] - 这些行为导致PYLARIFY的价格点、收入和整体增长潜力面临风险 [2] 诉讼程序信息 - 投资者可在2025年11月10日前申请成为主要原告代表 主要原告通常是具有最大经济利益且符合投资者类别典型性的个人或小组 [3] - 是否担任主要原告不影响分享任何赔偿的资格 [3] 律师事务所背景 - Kessler Topaz Meltzer & Check, LLP在国内外法院处理集体诉讼案件 已为欺诈和企业不当行为受害者追回数十亿美元 [4][5] - 该律所专注于保护投资者、消费者和员工免受企业欺诈、滥用职权和过失行为侵害 [5] 其他相关诉讼 - 该律所同时对Dow Inc (NYSE: DOW)提起证券集体诉讼 涉及2025年1月30日至2025年7月23日期间的证券交易 [8] - 对Centene Corporation (NYSE: CNC)的集体诉讼涉及2024年12月12日至2025年6月30日期间的证券交易 主要原告截止日期为2025年9月8日 [9][11] - 正在调查Fortinet, Inc (NASDAQ: FTNT)可能违反联邦证券法的行为 因其2025年第二季度财务业绩未达预期且多家分析师下调评级 [12]

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Lantheus Holdings, Inc. ("Lantheus†or the "Company†) (NASDAQ: LNTH) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON LANTHEUS HOLDINGS, INC. (LNTH), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 7, 2025, Lantheus released its first quarter 2025. ...

LOS ANGELES, Sept. 11, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Lantheus Holdings, Inc., investors ("Lantheus" or the "Company") (NASDAQ: LNTH) investors of a class action representing investors that bought securities between February 26, 2025, and August 5, 2025, inclusive (the “Class Period”). Lantheus investors have until November 10th, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, ...

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Lantheus business and prospects, resulting in its stock trading at inflated prices. ...

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/ ...

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or “the Company”) (NASDAQ: LNTH) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lant ...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025. Lantheus describes itself as a "global company that develops, manufactures, sells, and distributes certain diagnostic and therapeutic products.†For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. ...

公司业务与产品 - Lantheus Holdings Inc开发、制造和商业化诊断和治疗产品 协助全球临床医生诊断和治疗心脏病、癌症和其他疾病 [3] - 公司关键放射性药物肿瘤产品是Pylarify 一种用于协助诊断和治疗前列腺癌的PET显像剂 [3] 财务表现与业绩指引 - 2025年5月7日公司报告第一季度业绩 披露Pylarify销售额因"暂时性竞争干扰"而同比下降 [5] - 公司因Pylarify销售不及预期下调全年指引 从"低个位数至中个位数增长"调整为"持平至低个位数增长" [5] - 2025年8月6日公司再次宣布令人失望的业绩 Pylarify销售额同比下降8.3% 并进一步削减2025财年增长预期 [6] 股价表现 - 2025年5月7日业绩公布后 Lantheus股价下跌超过23% [5] - 2025年8月6日业绩更新后 Lantheus股价下跌近29% [6] 法律诉讼 - 针对Lantheus Holdings Inc的集体诉讼案件编号为25-cv-07491 由Margolis诉Lantheus Holdings Inc [1] - 诉讼指控公司及高管违反1934年证券交易法 称其创造了关于收入前景和增长预期的虚假印象 [4] - 诉讼称公司对Pylarify的市场定价和竞争动态缺乏准确理解 其销售增长潜力和价格正常化的乐观报告不符合现实 [4] - 集体诉讼期间为2025年2月26日至2025年8月5日 投资者可在2025年11月10日前申请担任首席原告 [1][7]